Developer docs
API playgroundTry for free, no card

Search company profiles

EXCITE INTERNATIONAL LTD

Full company profile

uuid025pcna

Namestring
EXCITE INTERNATIONAL LTD
Legal namestring
EXCITE International
Company typeenum
Private
Founded yearint
2016
Descriptiontext

EXCITE International Ltd is a Canadian not-for-profit, incorporated in March 2016 and headquartered in Toronto, that operates a global collaboration platform designed to accelerate the adoption of innovative medical technologies. The organization runs a pre-market harmonized evaluation pathway that brings together regulators, payers, health systems, clinical experts, and patients to provide coordinated feedback to medical device innovators before they commit to costly clinical trials. EXCITE's core offering is a three-stage service pathway: (1) the Early Technology Review (ETR), a confidential ~16-week advisory process that delivers payer, health system, expert, and patient feedback at proof-of-concept stage; (2) Protocol Development, which designs clinical trial protocols incorporating multi-stakeholder evidentiary requirements; and (3) Clinical Trial Development and Execution, which operationalizes protocols through partner networks including the Baim Institute (7,000+ U.S. sites), Radboud UMC, Nordic Proof, and NHS/ABHI-linked UK infrastructure. Technology is methodological rather than productized: EXCITE does not develop proprietary software products but rather a process platform codified through guidance documents, framework IP, and a 200+ person expert panel.

The commercial model is professional-services based, with fees custom-quoted per project scope across the ETR, protocol development, and clinical trial oversight workstreams. Customers are medical technology innovators ranging from multinational enterprises to SMEs and startups; EXCITE has engaged with over 100 such companies cumulatively, including named engagements with Izotropic Corporation, SoftOx Solutions, and Mode Sensors. The buyer ecosystem extends beyond innovators to a structured committee architecture (Executive Board, Payers' Advisory Committee spanning 5+ countries, International Scientific Collaboration, Industry Advisory Committee, Advisory Council) that gives EXCITE direct institutional access to the largest U.S. payers (BCBS, Aetna/CVS, Kaiser Permanente, CMS) and regulators including FDA CDRH, where EXCITE holds membership in the Early Payor Feedback Program since November 2022. Go-to-market is consultative and relationship-driven, leveraging partnerships with industry associations (AdvaMed, MDMA, MedTech Canada, MDIC), international partner hubs in Norway (Norway HealthTech) and the Netherlands (Radboud UMC), and recurring summits (2016 Toronto, 2019 Washington DC, 2021, 2023 Technology & Standards Forum). The 1-10 employee footprint indicates a lean operating model consistent with a coordinating not-for-profit rather than a scaled advisory firm.

Short descriptiontext

EXCITE International Ltd is a Canadian not-for-profit that operates a global pre-market evaluation platform for innovative medical technologies, coordinating payer, regulator, health system, and clinical expert input through Early Technology Reviews, multi-stakeholder protocol development, and clinical trial execution services for medical device innovators.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
health technology evaluation, pre-market advisory services, clinical trial protocol design, medical device assessment, multi-stakeholder health review
Industry3 codes
PRIMARYHLAGAOAN
Market Access, Pricing & Reimbursement (Evidence Generation) FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLACAOAN
Regulatory Submissions & Clinical Content Management (eCTD/Publishing)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services54169
  • Management Consulting Services54161
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Management Consulting Services8742
Product category
Health Technology Assessment & Advisory Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Early Technology Review Services
TypeProfessional Services
Description

EXCITE International offers confidential Early Technology Reviews to medical technology companies. Companies submit applications and work directly with EXCITE's expert panels. Pricing varies based on complexity and scope of the review.

exciteinternational.com
2Protocol Development Services
TypeProfessional Services
Description

EXCITE matches approved companies with Global Methodology Resource Centers (GMRCs) to develop custom clinical trial protocols. Costs vary depending on technology complexity, scope of services, and number of sites/partners involved.

exciteinternational.com
3Clinical Trial Oversight
TypeProfessional Services
Description

EXCITE International provides oversight of clinical trials through designated Clinical Research Organizations and health system clinical trial networks. Revenue is variable based on project scope.

exciteinternational.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Technology Screening/Prioritization Phase - approximately 2 months duration
ModelOtherBilling cadenceMulti-year contract
Notes

Comprehensive due diligence conducted by EXCITE International Secretariat before applications are brought forward to stakeholder committees. Review and prioritization phase typically takes about two months depending on technology complexity.

exciteinternational.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EXCITE International delivers pre-market evaluation and advisory services for innovative medical technologies through three integrated offerings: a confidential Early Technology Review (ETR) (~16 weeks) that gathers payer, health system, clinical expert, and patient feedback; customized multi-stakeholder Protocol Development for clinical trials; and Clinical Trial Development and Execution via Global Methodology Resource Centers and clinical trial networks. The services are sold primarily to medical device multinational enterprises and SMEs seeking accelerated adoption with reduced payer rejection risk.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Faster technology adoption timelines through pre-market harmonized approach
+2 more records
Product overview1 text field

EXCITE International is a not-for-profit global collaboration offering a pre-market harmonized approach to health technology evaluation and adoption. The core offerings include the Early Technology Review (ETR), Protocol Development, and Clinical Trial Development and Execution services. These services work together as an integrated pathway: ETR provides early-stage technology assessment and stakeholder feedback; Protocol Development creates customized clinical trial protocols incorporating multi-stakeholder input; and Clinical Trial Execution implements the protocols through EXCITE's international network of methodology centers and clinical trial sites. This unified approach is designed to expedite the pathway from innovation to regulatory approval and payer adoption for medical technologies.

Product and service3 records
1Early Technology Review (ETR)
CategoryPre-market health technology advisory
Description

A confidential review process providing medical technology companies with feedback from payers, health systems, expert end-users, and patients on their technology at the proof-of-concept stage. The ETR typically takes 16 weeks to complete and provides insights into evidentiary needs, ecosystem expectations, and downstream cost considerations.

2Multi-Stakeholder Protocol Development
CategoryClinical trial protocol design
Description

Customized clinical trial protocol design incorporating input from international payers, health systems, the scientific community, usability experts, safety and quality assurance experts, key opinion leaders, regulators, and patients. The protocols harmonize regulatory and coverage determinations through a single process.

3Clinical Trial Development and Execution
CategoryClinical trial execution services
Description

Execution of clinical trial protocols through designated Clinical Research Organizations and health system clinical trial networks, leveraging world-class methodological centers and EXCITE International's network of international partners across member countries.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-23
Description

EXCITE International became member of FDA's Early Payor Feedback Program (EPFP) in November 2022. The voluntary program allows medical device sponsors to obtain payor input on clinical trial design. EXCITE is now additional resource for companies making CDRH applications who wish to undertake ETR in preparation for clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-06
Description

EXCITE International and Izotropic Corporation announced partnership in April 2021. Izotropic engages with EXCITE's global network to align device, clinical trial design, and regulatory strategy with potential payor groups, methodologists, and expert end-users. The aim is to integrate inputs from various groups to increase potential breadth and speed of adoption upon regulatory approval.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-08-22
Description

Insperanto collaborates with EXCITE International to help tech companies engage with expert panels of decision makers to understand evidentiary needs before spending on development and IP.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-06-01
Description

EXCITE expanded collaboration with Baim Institute in 2018. The Harvard-associated institute conducts clinical trials following completion of EXCITE Early Technology Reviews. Baim Institute serves as default clinical trials center for U.S. EXCITE provides clinical trial execution through this partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-01
Description

EXCITE International strengthening partnership with MaRS EXCITE in Canada through MOU. The original MaRS EXCITE program was initiated by Dr. Leslie Levin in 2011 at MaRS Development District in Toronto.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-03-01
Description

MOU concluded in March 2018 between Norway HealthTech and EXCITE International, expected to evolve into EXCITE Norway and expand to include other Nordic Countries. Norway HealthTech profiles opportunities to Norwegian companies to access the U.S. market through EXCITE programs. SoftOx and Mode Sensors have completed Early Technology Reviews through this partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-03-01
Description

MOU concluded in March 2018 between Radboud University Medical Center in Nijmegen and EXCITE International. Provides health economic analysis as part of services offered to client companies. The relationship evolved into broader Netherlands partnership involving Hii Netherlands, MedValue, and REshape Center for patient engagement.

8Nordic Proof Clinical Trials Network
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-01-01
Description

Nordic Proof clinical trials network was added as an EXCITE International partner through Norway HealthTech. Provides clinical trial network capabilities for Nordic region studies.

exciteinternational.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Representatives from Blue Cross Blue Shield Association participate on the Payers' Advisory Committee. Dr. Naomi Aronson, Executive Director of Clinical Evaluation, Innovation, and Policy at BCBSA, is a founding member and past chair of PAC.

10Aetna/CVS
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Representatives from Aetna/CVS participate on the Payers' Advisory Committee. Dr. Robert McDonough, Senior Director for Clinical Policy Research and Development, serves as PAC Chair.

exciteinternational.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Representatives from Kaiser Permanente participate on the Payers' Advisory Committee. Dr. Jo Carol Hiatt, former Chair of Inter-Regional New Technology Committee, succeeded Naomi Aronson as PAC Chair.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Representatives from CMS participate on the Payers' Advisory Committee. Lori Ashby, Senior Advisor in Coverage and Analysis Group, leads development of Transitional Coverage for Emerging Technologies (TCET) pathway.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

EXCITE has close working relationship with MDIC, focused on patient engagement discussions with Yale Medical School CORE program and Patient Centered Research Foundation to develop access to patient outcomes data for technology evaluation.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2015-01-01
Description

EXCITE maintains close association with AdvaMed for industry engagement and advocacy.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2015-01-01
Description

EXCITE maintains close working relationship with MDMA for industry engagement and representing interests of medical device manufacturers.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2015-01-01
Description

EXCITE enjoys collaboration with MedTech Canada and an associate working on behalf of EXCITE to profile opportunities to Canadian industry.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

EXCITE enjoys collaboration with Ozmosis Research Inc for Canadian market engagement.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

EXCITE enjoys interaction with NHS through representation on Payers' Advisory Committee, Association of British HealthTech Industries on Advisory Council, and clinical trial experts from Oxford and Glasgow Universities.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2015-01-01
Description

ABHI has representation on the EXCITE Advisory Council, providing UK industry perspective and connections.

20ECRI Institute
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

EXCITE has partnership discussions with ECRI Institute for market development and technology assessment expertise.

exciteinternational.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1NAMSA
TypeBroad incumbent
Description

NAMSA is the largest global medical-device-focused Contract Research Organization, offering regulatory, clinical trial, and quality services to MedTech sponsors. EXCITE overlaps with NAMSA at the clinical trial design and execution stage but precedes it with the multi-stakeholder evidence alignment, positioning EXCITE upstream in the development pathway.

2CADTH (Canadian Agency for Drugs and Technologies in Health)
TypeDirect peer
Description

CADTH is Canada's health technology assessment agency that evaluates the clinical, economic, and patient evidence for new health technologies. EXCITE's pre-market, stakeholder-harmonized approach complements (and partially overlaps with) CADTH's post-market HTA role, making them functional peers in evidence evaluation for Canadian MedTech adoption.

TypeEmerging player
Description

Mtech Access is a UK-based specialist market access consultancy focused on medical devices and diagnostics, supporting HTA submissions and payer negotiations. Its services overlap with EXCITE's payer-engagement focus but at a smaller scale and primarily within the UK/European market.

TypeBroad incumbent
Description

IQVIA is the largest global CRO with extensive real-world evidence, market access, and health economics consulting practices serving MedTech sponsors. The evidence-generation and stakeholder-coordination capabilities compete broadly with EXCITE, though IQVIA operates at vastly greater scale and through a for-profit commercial model.

TypeBroad incumbent
Description

ICON is a global CRO that acquired PRA Health Sciences, offering clinical trial design, evidence generation, and commercial readiness services for MedTech and biopharma. ICON competes for clinical execution work that downstream follows EXCITE protocol design, putting it in adjacent competitive position.

6ECRI Institute
TypeDirect peer
Description

ECRI is an independent nonprofit that produces health technology assessments, clinical evidence evaluations, and patient safety guidance for hospitals and payers. Like EXCITE, ECRI serves as an evidence intermediary between developers and payers/health systems, making it a closely comparable HTA peer.

TypeOthers
Description

HTAi is the global professional society for health technology assessment practitioners and researchers, hosting the annual HTAi conference where EXCITE has presented. It is an ecosystem participant rather than a competitor, but its methodological standards and membership base interact meaningfully with EXCITE's evidence-alignment methodology.

TypeDirect peer
Description

NICE is the UK's HTA body providing evidence-based guidance on health technologies for NHS adoption. EXCITE's payer advisory mechanism with NHS membership and UK clinical experts (Oxford, Glasgow) is functionally a pre-market parallel to NICE's appraisal process, making them direct peers in payer/HTA-aligned evidence generation.

TypeOthers
Description

Baim is a Harvard-affiliated clinical research institute that operates as the default trial-execution partner for EXCITE's protocol designs, leveraging a 7,000-site worldwide network and 60 prior FDA submissions. As an implementation partner in EXCITE's pathway, Baim is adjacent and ecosystem-coupled rather than directly competitive.

TypeDirect peer
Description

MDIC is a US-based nonprofit public-private partnership that convenes FDA, NIH, CMS, industry, and patient groups to advance regulatory science for medical devices. Like EXCITE, MDIC focuses on resolving evidence-generation gaps between regulators, payers, and patients across MedTech, making it the closest direct peer in mission and stakeholder model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EXCITE INTERNATIONAL LTD

Health Technology Assessment & Advisory Servicesexciteinternational.com

EXCITE International Ltd is a Canadian not-for-profit that operates a global pre-market evaluation platform for innovative medical technologies, coordinating payer, regulator, health system, and clinical expert input through Early Technology Reviews, multi-stakeholder protocol development, and clinical trial execution services for medical device innovators.

What EXCITE INTERNATIONAL LTD does

EXCITE International Ltd is a Canadian not-for-profit, incorporated in March 2016 and headquartered in Toronto, that operates a global collaboration platform designed to accelerate the adoption of innovative medical technologies. The organization runs a pre-market harmonized evaluation pathway that brings together regulators, payers, health systems, clinical experts, and patients to provide coordinated feedback to medical device innovators before they commit to costly clinical trials. EXCITE's core offering is a three-stage service pathway: (1) the Early Technology Review (ETR), a confidential ~16-week advisory process that delivers payer, health system, expert, and patient feedback at proof-of-concept stage; (2) Protocol Development, which designs clinical trial protocols incorporating multi-stakeholder evidentiary requirements; and (3) Clinical Trial Development and Execution, which operationalizes protocols through partner networks including the Baim Institute (7,000+ U.S. sites), Radboud UMC, Nordic Proof, and NHS/ABHI-linked UK infrastructure. Technology is methodological rather than productized: EXCITE does not develop proprietary software products but rather a process platform codified through guidance documents, framework IP, and a 200+ person expert panel.

The commercial model is professional-services based, with fees custom-quoted per project scope across the ETR, protocol development, and clinical trial oversight workstreams. Customers are medical technology innovators ranging from multinational enterprises to SMEs and startups; EXCITE has engaged with over 100 such companies cumulatively, including named engagements with Izotropic Corporation, SoftOx Solutions, and Mode Sensors. The buyer ecosystem extends beyond innovators to a structured committee architecture (Executive Board, Payers' Advisory Committee spanning 5+ countries, International Scientific Collaboration, Industry Advisory Committee, Advisory Council) that gives EXCITE direct institutional access to the largest U.S. payers (BCBS, Aetna/CVS, Kaiser Permanente, CMS) and regulators including FDA CDRH, where EXCITE holds membership in the Early Payor Feedback Program since November 2022. Go-to-market is consultative and relationship-driven, leveraging partnerships with industry associations (AdvaMed, MDMA, MedTech Canada, MDIC), international partner hubs in Norway (Norway HealthTech) and the Netherlands (Radboud UMC), and recurring summits (2016 Toronto, 2019 Washington DC, 2021, 2023 Technology & Standards Forum). The 1-10 employee footprint indicates a lean operating model consistent with a coordinating not-for-profit rather than a scaled advisory firm.

EXCITE INTERNATIONAL LTD firmographics

Firmographics
Name
EXCITE INTERNATIONAL LTD
Legal name
EXCITE International
Website
https://exciteinternational.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
EXCITE International Ltd is a Canadian not-for-profit that operates a global pre-market evaluation platform for innovative medical technologies, coordinating payer, regulator, health system, and clinical expert input through Early Technology Reviews, multi-stakeholder protocol development, and clinical trial execution services for medical device innovators.
Ownership category
akta.pro rank

EXCITE INTERNATIONAL LTD industry classification

Industry
Product category
Health Technology Assessment & Advisory Services
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAGAOAN
Market Access, Pricing & Reimbursement (Evidence Generation) FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLACAOAN
Regulatory Submissions & Clinical Content Management (eCTD/Publishing)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Health technology evaluation
  • Pre-market advisory services
  • Clinical trial protocol design
  • Medical device assessment
  • Multi-stakeholder health review

Where EXCITE INTERNATIONAL LTD is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

EXCITE INTERNATIONAL LTD business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Early Technology Review Services: EXCITE International offers confidential Early Technology Reviews to medical technology companies. Companies submit applications and work directly with EXCITE's expert panels. Pricing varies based on complexity and scope of the review.
  2. Protocol Development Services: EXCITE matches approved companies with Global Methodology Resource Centers (GMRCs) to develop custom clinical trial protocols. Costs vary depending on technology complexity, scope of services, and number of sites/partners involved.
  3. Clinical Trial Oversight: EXCITE International provides oversight of clinical trials through designated Clinical Research Organizations and health system clinical trial networks. Revenue is variable based on project scope.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractTechnology Screening/Prioritization Phase - approximately 2 months duration

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

EXCITE INTERNATIONAL LTD product offering

Product offering

Core offering

EXCITE International delivers pre-market evaluation and advisory services for innovative medical technologies through three integrated offerings: a confidential Early Technology Review (ETR) (~16 weeks) that gathers payer, health system, clinical expert, and patient feedback; customized multi-stakeholder Protocol Development for clinical trials; and Clinical Trial Development and Execution via Global Methodology Resource Centers and clinical trial networks. The services are sold primarily to medical device multinational enterprises and SMEs seeking accelerated adoption with reduced payer rejection risk.

Product overview

EXCITE International is a not-for-profit global collaboration offering a pre-market harmonized approach to health technology evaluation and adoption. The core offerings include the Early Technology Review (ETR), Protocol Development, and Clinical Trial Development and Execution services. These services work together as an integrated pathway: ETR provides early-stage technology assessment and stakeholder feedback; Protocol Development creates customized clinical trial protocols incorporating multi-stakeholder input; and Clinical Trial Execution implements the protocols through EXCITE's international network of methodology centers and clinical trial sites. This unified approach is designed to expedite the pathway from innovation to regulatory approval and payer adoption for medical technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early Technology Review (ETR) A confidential review process providing medical technology companies with feedback from payers, health systems, expert end-users, and patients on their technology at the proof-of-concept stage. The ETR typically takes 16 weeks to complete and provides insights into evidentiary needs, ecosystem expectations, and downstream cost considerations.
  • Multi-Stakeholder Protocol Development Customized clinical trial protocol design incorporating input from international payers, health systems, the scientific community, usability experts, safety and quality assurance experts, key opinion leaders, regulators, and patients. The protocols harmonize regulatory and coverage determinations through a single process.
  • Clinical Trial Development and Execution Execution of clinical trial protocols through designated Clinical Research Organizations and health system clinical trial networks, leveraging world-class methodological centers and EXCITE International's network of international partners across member countries.

Quantifiable outcome

  • Faster technology adoption timelines through pre-market harmonized approach
  • +2 more outcomes

Companies that use EXCITE INTERNATIONAL LTD

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

EXCITE INTERNATIONAL LTD technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

EXCITE INTERNATIONAL LTD partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered core and minor.

  • FDA Center for Devices and Radiological Health (CDRH)coreStrategic or Co-development Partner · 23 November 2022EXCITE International became member of FDA's Early Payor Feedback Program (EPFP) in November 2022. The voluntary program allows medical device sponsors to obtain payor input on clinical trial design. EXCITE is now additional resource for companies making CDRH applications who wish to undertake ETR in preparation for clinical trials.
  • Izotropic CorporationcoreStrategic or Co-development Partner · 6 April 2021EXCITE International and Izotropic Corporation announced partnership in April 2021. Izotropic engages with EXCITE's global network to align device, clinical trial design, and regulatory strategy with potential payor groups, methodologists, and expert end-users. The aim is to integrate inputs from various groups to increase potential breadth and speed of adoption upon regulatory approval.
  • InsperantominorStrategic or Co-development Partner · 22 August 2019Insperanto collaborates with EXCITE International to help tech companies engage with expert panels of decision makers to understand evidentiary needs before spending on development and IP.
  • Baim Institute of Clinical ResearchcoreImplementation/ SI/ Consulting Partner · 1 June 2018EXCITE expanded collaboration with Baim Institute in 2018. The Harvard-associated institute conducts clinical trials following completion of EXCITE Early Technology Reviews. Baim Institute serves as default clinical trials center for U.S. EXCITE provides clinical trial execution through this partnership.
  • MaRS EXCITEcoreStrategic or Co-development Partner · 1 June 2018EXCITE International strengthening partnership with MaRS EXCITE in Canada through MOU. The original MaRS EXCITE program was initiated by Dr. Leslie Levin in 2011 at MaRS Development District in Toronto.
  • Norway HealthTechcoreStrategic or Co-development Partner · 1 March 2018MOU concluded in March 2018 between Norway HealthTech and EXCITE International, expected to evolve into EXCITE Norway and expand to include other Nordic Countries. Norway HealthTech profiles opportunities to Norwegian companies to access the U.S. market through EXCITE programs. SoftOx and Mode Sensors have completed Early Technology Reviews through this partnership.
  • Radboud University Medical CentercoreStrategic or Co-development Partner · 1 March 2018MOU concluded in March 2018 between Radboud University Medical Center in Nijmegen and EXCITE International. Provides health economic analysis as part of services offered to client companies. The relationship evolved into broader Netherlands partnership involving Hii Netherlands, MedValue, and REshape Center for patient engagement.
  • Nordic Proof Clinical Trials NetworkminorImplementation/ SI/ Consulting Partner · 1 January 2018Nordic Proof clinical trials network was added as an EXCITE International partner through Norway HealthTech. Provides clinical trial network capabilities for Nordic region studies.
  • Blue Cross Blue Shield AssociationcoreStrategic or Co-development Partner · 1 January 2015Representatives from Blue Cross Blue Shield Association participate on the Payers' Advisory Committee. Dr. Naomi Aronson, Executive Director of Clinical Evaluation, Innovation, and Policy at BCBSA, is a founding member and past chair of PAC.
  • Aetna/CVScoreStrategic or Co-development Partner · 1 January 2015Representatives from Aetna/CVS participate on the Payers' Advisory Committee. Dr. Robert McDonough, Senior Director for Clinical Policy Research and Development, serves as PAC Chair.
  • Kaiser PermanentecoreStrategic or Co-development Partner · 1 January 2015Representatives from Kaiser Permanente participate on the Payers' Advisory Committee. Dr. Jo Carol Hiatt, former Chair of Inter-Regional New Technology Committee, succeeded Naomi Aronson as PAC Chair.
  • Centers for Medicare & Medicaid Services (CMS)coreStrategic or Co-development Partner · 1 January 2015Representatives from CMS participate on the Payers' Advisory Committee. Lori Ashby, Senior Advisor in Coverage and Analysis Group, leads development of Transitional Coverage for Emerging Technologies (TCET) pathway.
  • Medical Devices Innovation Consortium (MDIC)minorStrategic or Co-development Partner · 1 January 2015EXCITE has close working relationship with MDIC, focused on patient engagement discussions with Yale Medical School CORE program and Patient Centered Research Foundation to develop access to patient outcomes data for technology evaluation.
  • AdvaMedminorGTM or Marketing Partner · 1 January 2015EXCITE maintains close association with AdvaMed for industry engagement and advocacy.
  • Medical Device Manufacturers Association (MDMA)minorGTM or Marketing Partner · 1 January 2015EXCITE maintains close working relationship with MDMA for industry engagement and representing interests of medical device manufacturers.
  • MedTech CanadaminorGTM or Marketing Partner · 1 January 2015EXCITE enjoys collaboration with MedTech Canada and an associate working on behalf of EXCITE to profile opportunities to Canadian industry.
  • Ozmosis Research IncminorStrategic or Co-development Partner · 1 January 2015EXCITE enjoys collaboration with Ozmosis Research Inc for Canadian market engagement.
  • NHS (National Health Service)minorStrategic or Co-development Partner · 1 January 2015EXCITE enjoys interaction with NHS through representation on Payers' Advisory Committee, Association of British HealthTech Industries on Advisory Council, and clinical trial experts from Oxford and Glasgow Universities.
  • Association of British HealthTech IndustriesminorGTM or Marketing Partner · 1 January 2015ABHI has representation on the EXCITE Advisory Council, providing UK industry perspective and connections.
  • ECRI InstituteminorStrategic or Co-development Partner · 1 January 2015EXCITE has partnership discussions with ECRI Institute for market development and technology assessment expertise.

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

EXCITE INTERNATIONAL LTD competitors and assessment

Company assessment

Broad incumbents

  • NAMSA: NAMSA is the largest global medical-device-focused Contract Research Organization, offering regulatory, clinical trial, and quality services to MedTech sponsors. EXCITE overlaps with NAMSA at the clinical trial design and execution stage but precedes it with the multi-stakeholder evidence alignment, positioning EXCITE upstream in the development pathway.
  • IQVIA: IQVIA is the largest global CRO with extensive real-world evidence, market access, and health economics consulting practices serving MedTech sponsors. The evidence-generation and stakeholder-coordination capabilities compete broadly with EXCITE, though IQVIA operates at vastly greater scale and through a for-profit commercial model.
  • ICON plc: ICON is a global CRO that acquired PRA Health Sciences, offering clinical trial design, evidence generation, and commercial readiness services for MedTech and biopharma. ICON competes for clinical execution work that downstream follows EXCITE protocol design, putting it in adjacent competitive position.

Direct peers

  • CADTH (Canadian Agency for Drugs and Technologies in Health): CADTH is Canada's health technology assessment agency that evaluates the clinical, economic, and patient evidence for new health technologies. EXCITE's pre-market, stakeholder-harmonized approach complements (and partially overlaps with) CADTH's post-market HTA role, making them functional peers in evidence evaluation for Canadian MedTech adoption.
  • ECRI Institute: ECRI is an independent nonprofit that produces health technology assessments, clinical evidence evaluations, and patient safety guidance for hospitals and payers. Like EXCITE, ECRI serves as an evidence intermediary between developers and payers/health systems, making it a closely comparable HTA peer.
  • NICE (National Institute for Health and Care Excellence): NICE is the UK's HTA body providing evidence-based guidance on health technologies for NHS adoption. EXCITE's payer advisory mechanism with NHS membership and UK clinical experts (Oxford, Glasgow) is functionally a pre-market parallel to NICE's appraisal process, making them direct peers in payer/HTA-aligned evidence generation.
  • Medical Devices Innovation Consortium (MDIC): MDIC is a US-based nonprofit public-private partnership that convenes FDA, NIH, CMS, industry, and patient groups to advance regulatory science for medical devices. Like EXCITE, MDIC focuses on resolving evidence-generation gaps between regulators, payers, and patients across MedTech, making it the closest direct peer in mission and stakeholder model.

Emerging players

  • Mtech Access: Mtech Access is a UK-based specialist market access consultancy focused on medical devices and diagnostics, supporting HTA submissions and payer negotiations. Its services overlap with EXCITE's payer-engagement focus but at a smaller scale and primarily within the UK/European market.

Others

  • HTAi (Health Technology Assessment International): HTAi is the global professional society for health technology assessment practitioners and researchers, hosting the annual HTAi conference where EXCITE has presented. It is an ecosystem participant rather than a competitor, but its methodological standards and membership base interact meaningfully with EXCITE's evidence-alignment methodology.
  • Baim Institute of Clinical Research: Baim is a Harvard-affiliated clinical research institute that operates as the default trial-execution partner for EXCITE's protocol designs, leveraging a 7,000-site worldwide network and 60 prior FDA submissions. As an implementation partner in EXCITE's pathway, Baim is adjacent and ecosystem-coupled rather than directly competitive.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EXCITE INTERNATIONAL LTD social profiles

Digital presence

EXCITE INTERNATIONAL LTD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EXCITE INTERNATIONAL LTD leadership team

Management profile

Number of profiles

Profiles4 records

EXCITE INTERNATIONAL LTD funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EXCITE INTERNATIONAL LTD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EXCITE INTERNATIONAL LTD

What does EXCITE INTERNATIONAL LTD do?

EXCITE International delivers pre-market evaluation and advisory services for innovative medical technologies through three integrated offerings: a confidential Early Technology Review (ETR) (~16 weeks) that gathers payer, health system, clinical expert, and patient feedback; customized multi-stakeholder Protocol Development for clinical trials; and Clinical Trial Development and Execution via Global Methodology Resource Centers and clinical trial networks. The services are sold primarily to medical device multinational enterprises and SMEs seeking accelerated adoption with reduced payer rejection risk.

Is EXCITE INTERNATIONAL LTD a public or private company?

EXCITE INTERNATIONAL LTD is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was EXCITE INTERNATIONAL LTD founded?

EXCITE INTERNATIONAL LTD was founded in 2016. It employs 1 to 10 people.

Where is EXCITE INTERNATIONAL LTD based?

EXCITE INTERNATIONAL LTD is headquartered in Toronto, Canada, in the North America region.

How does EXCITE INTERNATIONAL LTD make money?

Three revenue lines are on record. Early Technology Review Services are the primary driver. The others are protocol Development Services and clinical Trial Oversight.

Who are EXCITE INTERNATIONAL LTD's main competitors?

Broad incumbents on record are NAMSA, IQVIA and ICON plc. Direct peers are CADTH (Canadian Agency for Drugs and Technologies in Health), ECRI Institute, NICE (National Institute for Health and Care Excellence) and Medical Devices Innovation Consortium (MDIC). Mtech Access is listed as an emerging player. Others are HTAi (Health Technology Assessment International) and Baim Institute of Clinical Research.

Does EXCITE INTERNATIONAL LTD have an API?

No public API is recorded for EXCITE INTERNATIONAL LTD.

What industry is EXCITE INTERNATIONAL LTD in?

EXCITE INTERNATIONAL LTD's product category is Health Technology Assessment & Advisory Services. Its primary akta.pro industry code is HLAGAOAN, Market Access, Pricing & Reimbursement (Evidence Generation) FSP, with a secondary code of HLAGAOAA, Clinical Operations & Monitoring FSP (CRA/CTM/Start-up). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals